

Usefulness of Quantitative Endotracheal Aspirate Cultures in Intensive Care Unit Patients with Suspected Pneumonia

Yoon Mi Shin¹, Yeon-Mok Oh²,
Mi Na Kim³, Tae Sun Shim²,
Chae-Man Lim², Sang Do Lee²,
Younsuck Koh², Woo Sung Kim²,
Dong Soon Kim² and Sang-Bum Hong²

¹Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Cheongju St. Mary Hospital, Cheongju; ²Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine; ³Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Received: 13 January 2011

Accepted: 21 April 2011

Address for Correspondence:

Sang-Bum Hong, MD

Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Korea
Tel: +82.2-3010-3893, Fax: +82.2-3010-6968
E-mail: sbhong@amc.seoul.kr

It is difficult to differentiate pathogens responsible for pneumonia or colonization in patients with an endotracheal tube or in patients that have undergone tracheostomy. We evaluated the clinical usefulness of quantitative endotracheal aspirates cultures and sought to determine the result threshold level for positivity. The authors performed this retrospective cohort study between December 1, 2004 and January 31, 2006. Forty-five suspected pneumonia patients admitted to an intensive care unit (ICU) with quantitative bronchoalveolar lavage (BAL) and endotracheal aspirate (EA) culture results were enrolled. Using a threshold of 10^5 cfu/mL, 10 of the 45 (22.2%) quantitative EA cultures were positive, as compared with 7 (15.6%) BAL cultures. When BAL culture findings were used as the reference, the sensitivity and specificity of quantitative EA cultures were 85.7% and 89.5%, respectively, at a threshold of 10^5 cfu/mL, and 85.7% and 94.7%, respectively, at a threshold of 10^6 cfu/mL. Of the 10 EA culture positive patients, 2 patients with a result of $<10^5$ cfu/mL were BAL culture negative. The quantitative EA culture is a useful non-invasive tool for the diagnosis of pneumonia pathogens. It is suggested that a threshold level of 10^6 cfu/mL is appropriate.

Key Words: Quantitative Culture; Endotracheal Aspirate; Pneumonia

INTRODUCTION

The accurate diagnosis of newly developed pneumonia is difficult in patients with an endotracheal tube or tracheostomy (1), since many other conditions, such as, tracheobronchitis (2), pulmonary edema, and atelectasis, can mimic pneumonia. Therefore bacteriologic tests are necessary to confirm pneumonia; Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) guideline is that samples of lower respiratory tract secretions should be obtained from all patients with suspected hospital acquired pneumonia (HAP) which should be collected before antibiotic changes. Samples can include an endotracheal aspirate, bronchoalveolar lavage sample, or protected specimen brush sample (2).

But qualitative endotracheal aspirate (EA) culture cannot differentiate colonization from infection (3, 4). Although quantitative culture of bronchoalveolar lavage (BAL) fluid obtained by bronchoscopy can accurately diagnose pneumonia, this procedure is invasive and cannot be utilized in some patients, especially in those who are critical (5-12).

Quantitative EA culture is non-invasive, easily learnt, and cheaper than quantitative BAL fluid culture (4, 13); and previ-

ous results have suggested that EA can be used as a substitute for BAL in quantitative cultures (4). However, this issue is controversial and result thresholds have not been determined. Furthermore, little data is available on quantitative EA cultures in Korea, or on the clinical applications of this methodology. Accordingly, we evaluated the clinical usefulness of quantitative EA cultures in intensive care unit (ICU) patients with pneumonia, and sought to determine the result threshold level for positivity.

MATERIALS AND METHODS

We performed this retrospective cohort study between December 1, 2004 and January 31, 2006. Patients with an endotracheal tube or tracheostomy suspected of having pneumonia admitted to medical ICU at the Asan Medical Center were enrolled whose EA sample was collected within 2 days of a BAL sample. Patients with community acquired, hospital acquired, and health care associated pneumonia were included, as were immunocompromised or immunocompetent patients, who had previously received antibiotics. However, patients with a lower clinical pulmonary infection score (CPIS) of <6 or with an interval between

BAL fluid and EA sampling of > 48 hr were excluded.

We evaluated patient demographic data, hospital courses, microbiologic results, the use of antibiotics, and radiographic changes. Acute physiology and chronic health evaluation (APACHE) II scores were determined at ICU admission, and CPIS scores on the first and third days after the onset of hospital acquired pneumonia.

EA samples with > 10 epithelial cells per low power field on a Gram stained slide of a direct smear were rejected as inadequate for culture. EA cultures were quantified using calibrated loops. Briefly, each 1 microliter of EA itself and 100-fold diluted EA were evenly streaked with 1 microliter-disposable plastic loop on entire surface of a chocolate agar plate, a sheep blood agar plate, and a MacConkey agar plate. Plates are incubated overnight in a 5% CO₂ atmosphere at 35°C. Colonies were then counted and bacterial concentrations (cfu/mL) were calculated. Microorganisms with counts > 10⁴ cfu/mL were submitted for identification and antimicrobial susceptibility testing. If no growth was detected on any plate, the incubation was extended for 24 hr.

Statistical analysis was performed using SPSS version 10.0 (SPSS, Chicago, IL, USA). Results are expressed as means ± SDs. The chi-square test was used to compare proportions. Threshold levels of 10⁵, 10⁶, and 10⁷ cfu/mL were used to evaluate quanti-

tative EA culture positivity, but quantitative BAL culture positivity was defined as 10⁴ cfu/mL, which is an established threshold level. Sensitivity, specificity, and the predictive values of quantitative EA cultures were calculated at each of the three threshold levels. Kappa analysis was used to determine concordance rates between quantitative EA and BAL culture results.

Ethics statement

This study protocol was approved by the institutional review board (IRB) of Asan Medical Center (Approval number: 2011-0170). This study was exempted from written informed consent and all the data collected from this study was kept confidential.

RESULTS

A total of 45 patients (32 men, 13 women, mean age 63.4 ± 13.2 yr) were enrolled. Patient demographic data is provided in Table 1. Twenty-eight patients had hospital acquired pneumonia and 17 had community acquired pneumonia (CAP). Their underlying diseases included malignancy, chronic lung disease, rheumatologic disease, and others. The majority of patients (n = 36) were immunocompromised, and 17 of these had previously received chemotherapeutic agents, corticosteroids, or immunosuppressive agents. The major cause of ICU admission was respiratory failure and hypoxemia. Total patients' mean APACHE II score at ICU admission was 29.4 ± 7.3. In patients with hospital acquired pneumonia, mean CPIS scores on days 1 and 3 after pneumonia onset were 8.7 ± 2.0 and 8.5 ± 2.0, respectively.

Table 2 shows the hospital courses of the patients. Mean length of ICU stay was 29.8 ± 26.8 days and mean duration of mechanical ventilation was 26.4 ± 25.3 days. The average time between BAL and EA sampling was 0.2 ± 0.9 days. Using a threshold of 10⁵ cfu/mL, 10 (22.2%) quantitative EA cultures were positive, as compared with 7 (15.6%) BAL cultures (Table 3). Six of the 7 patients with a positive BAL cultures had a positive EA culture. Of the 10 EA culture (+) patients, 2 patients with 10⁵ cfu/mL had all BAL culture (-), and of the 8 EA culture (+) patients (at a thresh-

Table 1. Patient demographics and clinical characteristics at baseline

Clinical characteristics	Data
Total number	45
Age (yr)	63.4 ± 13.2
Sex (M/F)	32/13
Pneumonia	
HAP	28
CAP	17
Underlying disease	
Malignancy	19
Chronic lung disease	8
Transplantation recipient	2
Rheumatologic disease	4
Gastrointestinal disease	4
History of malignancy	3
Stroke	3
Other	2
Immune status	
Immuno-competent	9
Immuno-compromised	36
Previous medication	
Steroid	5
Chemotherapeutic agent	8
Immunosuppressant	4
None	28
Previous antibiotics	
Yes	29
No	16
Cause of ICU care	
Respiratory failure and hypoxemia	36
Shock	3
Close monitoring	4
Post-operation	2

HAP, hospital acquired pneumonia; CAP, community acquired pneumonia.

Table 2. Patient characteristics at ICU admission, clinical pulmonary infection score (CPIS) on days 1 and 3 after pneumonia onset in patients with hospital acquired pneumonia and hospital courses (days)

Parameters	Mean ± SD
APACHE II score on ICU admission	29.4 ± 7.3
CPIS (n = 28)	
Day 1	8.7 ± 2.0
Day 3	8.5 ± 2.0
Hospital days	
Duration of ICU stay	29.8 ± 26.8
Duration of mechanical ventilation	26.4 ± 25.3
Duration of mechanical ventilation before BAL (total)	8.1 ± 14.0
In HAP	11.8 ± 17.0
In CAP	2.2 ± 2.3
Time between BAL and EA	0.2 ± 0.9

SD, standard deviation.

Table 3. Microbiologic results of quantitative cultures, previous antibiotics duration (days) before BAL and type of pneumonia in patients with positive culture


Patient number	EA	Q*	BAL	Q	Previous antibiotics duration (days)	Type of pneumonia
1	MRSA	3×10^5	0	0	7	HAP
8	MRSA	1.5×10^6	MRSA	4×10^5	> 7	HAP
9	IRPA	2.5×10^6	IRPA	1×10^7	0	HAP
10	<i>S. maltophilia</i>	5×10^6	0	0	> 7	HAP
12	IRPA	1×10^6	IRPA	1×10^6	> 7	HAP
16	<i>A. baumannii</i>	5×10^7	<i>A. baumannii</i>	1.4×10^6	> 7	HAP
24	ESBL	2×10^6	ESBL	5×10^4	> 7	HAP
28	<i>P. aeruginosa</i>	6×10^5	0	0	5	CAP
31	<i>S. maltophilia</i>	2×10^6	<i>S. maltophilia</i>	1×10^6	> 7	HAP
36	0	0	MRSA	5×10^5	> 7	HAP
43	<i>S. maltophilia</i>	5×10^6	<i>S. maltophilia</i>	4×10^3	> 7	HAP

*Culture counts. MRSA, methicillin resistant *Staphylococcus aureus*; IRPA, imipenem resistant *Pseudomonas aeruginosa*; ESBL, extended-spectrum β -lactamases.

Table 4. Characteristics of quantitative EA cultures and the concordance between quantitative BAL and EA cultures

Threshold	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	κ	P value	Concordance
$\geq 10^5$	85.7	89.5	60.0	97.1	0.64	0.00	Good
$\geq 10^6$	85.7	94.7	75.0	97.3	0.76	0.00	Excellent
$\geq 10^7$	14.3	100	100	86.4	0.22	0.018	Poor

PPV, positive predictive value; NPV, negative predictive value.

**Fig. 1.** ROC curve of quantitative EA culture.

old of 10^6 cfu/mL), 6 were BAL culture (+).

We calculated the diagnostic efficiencies of quantitative EA culture at each threshold level. When BAL culture findings were used as reference, the sensitivity and specificity of quantitative EA culture at a threshold of 10^5 cfu/mL were 85.7% and 89.5%, respectively and at a threshold of 10^6 cfu/mL, these were 85.7% and 94.7%, respectively (Table 4). Kappa analysis showed that the concordance rate of the two diagnostic methods was best at a quantitative EA culture threshold of 10^6 cfu/mL. The area under the ROC curve of quantitative EA culture at this threshold was 0.902 (Fig. 1).

After obtaining culture results, antibiotic regimens were al-

tered in 19 (42%) of the 45 patients. In 16 (36%) patients, antibiotics were deescalated and these included 12 patients on vancomycin because of a lack of evidence of methicillin-resistant *Staphylococcus aureus* infection. When we evaluated positivity rates with respect to time of antibiotic use before BAL, we observed higher positivity rate in patients who had received antibiotics for 7 days or longer ($P = 0.017$).

DISCUSSION

This study shows that quantitative endotracheal aspirate culture is a useful non-invasive tool for the diagnosis of pneumonia pathogens in critically ill patients. Our findings suggest that a threshold level of 10^6 cfu/mL is appropriate because at this level excellent concordance was found with quantitative BAL culture results.

Ventilator associated pneumonia (VAP) or severe CAP is difficult to diagnosis in ICU patients with an endotracheal tube or a tracheostomy. It is associated with high mortality and morbidity rates (14). Thus, early and accurate diagnosis and appropriate empirical antibiotic treatment are important outcome variables (14).

Many clinical conditions mimic pneumonia in these patients, which in practice, means that microbiologic evaluations are required for the diagnosis of pneumonia. However, it is difficult to obtain specimens from the lower respiratory tract without contamination by colonizing bacteria. Therefore culture results are invariably often difficult to interpret. Since qualitative cultures are unable to distinguish between pathogens and colonizing bacteria, the concept of quantitative culture was developed based

on BAL, protected specimen brush (PSB), blinded protected telescoping catheter, and EA cultures (15-21).

Quantitative EA cultures are straightforward, cheap, easily performed, and non-invasive and have been shown to be useful in Western countries (22-26). Previous studies included comparative evaluations of the accuracy of quantitative EA cultures for the diagnosis of VAP versus other diagnostic methods, such as, autopsy specimen, BAL, or PSB culture, or clinical methods (22, 24-28). In general, each of these methods is of clinical value, primarily because of the invasive nature of bronchoscopy (5-12), but their sensitivities and specificities vary. Additionally positivity thresholds are controversial, 10^5 cfu/mL (22, 26, 29), or 10^6 cfu/mL (24, 25, 27).

No reference autopsy specimen was available for this study. Therefore we used quantitative BAL cultures and clinical diagnosis as diagnostic standards to confirm the presence of pneumonia.

When we compared the sensitivity, specificity, and concordance of quantitative EA and quantitative BAL culture, we found that the optimal quantitative EA culture threshold level was 10^6 cfu/mL.

Furthermore, in patients with hospital acquired pneumonia, we also used CPIS (30). No patient with HAP had a CPIS score of < 6 on day 1 and 3 after pneumonia onset, so this study showed high specificity (94.7%) than previous studies that did not use it (24, 25, 27).

When 10^4 cfu/mL was used as a cutoff value for quantitative BAL cultures, we found that 15.6% of BAL cultures were positive, which is lower than previous studies. This may have been low because we do not routinely perform quantitative BAL culture in critically ill patients with suspected pneumonia. We performed quantitative BAL culture in ICU patients with a poor clinical response to a previous empirical regimen or atypical clinical symptoms or signs. So we might enrolled many difficult patients to diagnose or patients suspected of having an atypical pathogens. Furthermore, many of the cultured bacteria were drug resistant organisms. These may be partially explained by culture positivity rate was high in patients with prolonged antibiotic use rather than short term antibiotic use. Only one CAP patient showed positive EA culture and the others were HAP patients. We had more HAP patients (HAP 28/CAP 17 patients) and most of CAP patients received antibiotics initiation before BAL. When we included in patients with HAP only, EA and BAL culture rates were 32.1% and 25% respectively.

In our cohort, the antibiotic regimen was changed in 19 patients, including 12 maintained on antibiotics after vancomycin discontinuance, and these actions were taken based on our quantitative culture results. Thus, quantitative EA culture is likely to reduce antibiotic use.

Several study limitations should be borne in mind. First, this was not a randomized controlled study. Besides BAL was not

performed routinely in all patients with pneumonia or in patients that responded well to antibiotics due to its invasiveness. Accordingly, this study was performed in patients who had contracted a difficult pathogen to diagnose. In addition, we also included many patients who had been previously treated with antibiotics, and we enrolled community and hospital acquired pneumonia cases.

Summarizing, quantitative EA cultures are useful non-invasive diagnostic tool in critically ill patients with an endotracheal tube or tracheostomy suspected of having pneumonia especially in HAP. It is also suggested that the appropriate threshold level for quantitative EA culture is 10^6 cfu/mL.

REFERENCES

1. Baughman RP. *Diagnosis of ventilator-associated pneumonia. Microbes Infect* 2005; 7: 262-7.
2. American Thoracic Society; Infectious Diseases Society of America. *Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med* 2005; 171: 388-416.
3. Lambotte O, Timsit JF, Garrouste-Orgeas M, Misset B, Benali A, Carlet J. *The significance of distal bronchial samples with commensals in ventilator-associated pneumonia: colonizer or pathogen? Chest* 2002; 122: 1389-99.
4. Albert S, Kirchner J, Thomas H, Behne M, Schur J, Brade V. *Role of quantitative cultures and microscopic examinations of endotracheal aspirates in the diagnosis of pulmonary infections in ventilated patients. J Hosp Infect* 1997; 37: 25-37.
5. Tsai SH, Cohen SS, Fenger EP. *Bronchial perforation as a complication of bronchoscopy. Am Rev Tuberc* 1958; 78: 106-10.
6. Prakash UB, Offord KP, Stubbs SE. *Bronchoscopy in North America: the ACCP survey. Chest* 1991; 100: 1668-75.
7. Jolliet P, Chevrolet JC. *Bronchoscopy in the intensive care unit. Intensive Care Med* 1992; 18: 160-9.
8. Valentine VG, Rizk NW, Hancock EW. *A complication during bronchoscopy. Hosp Pract (Off Ed)* 1993; 28: 22, 27.
9. Pereira W, Kovnat DM, Khan MA, Iacovino JR, Spivack ML, Snider GL. *Fever and pneumonia after flexible fiberoptic bronchoscopy. Am Rev Respir Dis* 1975; 112: 59-64.
10. Kiss K, Pápai Z, Szima B, Kis S, Strausz J. *Fiberoptic bronchoscopy in intensive care units. Orv Hetil* 1996; 137: 1689-91.
11. Hammer DL, Aranda CP, Galati V, Adams FV. *Massive intrabronchial aspiration of contents of pulmonary abscess after fiberoptic bronchoscopy. Chest* 1978; 74: 306-7.
12. Friedman RL. *Selective pneumothorax: a complication of bronchoscopy. Dis Chest* 1955; 27: 213-5.
13. Bergmans DC, Bonten MJ, De Leeuw PW, Stobberingh EE. *Reproducibility of quantitative cultures of endotracheal aspirates from mechanically ventilated patients. J Clin Microbiol* 1997; 35: 796-8.
14. Chastre J, Fagon JY. *Ventilator-associated pneumonia. Am J Respir Crit Care Med* 2002; 165: 867-903.
15. Brun-Buisson C, Fartoukh M, Leclapt E, Honoré S, Zahar JR, Cerf C, Maitre B. *Contribution of blinded, protected quantitative specimens to the diagnostic and therapeutic management of ventilator-associated*

- pneumonia. *Chest* 2005; 128: 533-44.
16. Clec'h C, Jauréguy F, Hamza L, Karoubi P, Fosse JP, Hamdi A, Vincent F, Gonzalez F, Cohen Y. Agreement between quantitative cultures of post-intubation tracheal aspiration and plugged telescoping catheter, protected specimen brush, or BAL for the diagnosis of nosocomial pneumonia. *Chest* 2006; 130: 956-61.
 17. Cook D, Mandell L. Endotracheal aspiration in the diagnosis of ventilator-associated pneumonia. *Chest* 2000; 117(4 Suppl 2): 195S-7S.
 18. Elatrous S, Boukef R, Ouanes Besbes L, Marghli S, Nooman S, Nouira S, Abroug F. Diagnosis of ventilator-associated pneumonia: agreement between quantitative cultures of endotracheal aspiration and plugged telescoping catheter. *Intensive Care Med* 2004; 30: 853-8.
 19. Fangio P, Rouquette-Vincenti I, Rousseau JM, Soullié B, Brinquin L. Diagnosis of ventilator-associated pneumonia: a prospective comparison of the telescoping plugged catheter with the endotracheal aspirate. *Ann Fr Anesth Reanim* 2002; 21: 184-92.
 20. Fujitani S, Yu VL. Diagnosis of ventilator-associated pneumonia: focus on nonbronchoscopic techniques (nonbronchoscopic bronchoalveolar lavage, including mini-BAL, blinded protected specimen brush, and blinded bronchial sampling) and endotracheal aspirates. *J Intensive Care Med* 2006; 21: 17-21.
 21. Papazian L, Thomas P, Garbe L, Guignon I, Thirion X, Charrel J, Bollet C, Fuentes P, Gouin F. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1995; 152: 1982-91.
 22. el-Ebiary M, Torres A, González J, de la Bellacasa JP, García C, Jiménez de Anta MT, Ferrer M, Rodríguez-Roisin R. Quantitative cultures of endotracheal aspirates for the diagnosis of ventilator-associated pneumonia. *Am Rev Respir Dis* 1993; 148: 1552-7.
 23. Michel F, Franceschini B, Berger P, Arnal JM, Gannier M, Sainty JM, Papazian L. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. *Chest* 2005; 127: 589-97.
 24. Marquette CH, Georges H, Wallet F, Ramon P, Saulnier F, Neviere R, Mathieu D, Rime A, Tonnel AB. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia. Comparison with the protected specimen brush. *Am Rev Respir Dis* 1993; 148: 138-44.
 25. Torres A, Martos A, Puig de la Bellacasa J, Ferrer M, el-Ebiary M, González J, Gené A, Rodríguez-Roisin R. Specificity of endotracheal aspiration, protected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. *Am Rev Respir Dis* 1993; 147: 952-7.
 26. Savaia A, Moore FA, Moore EE, Haenel JB, Kaneer L, Read RA. Diagnosing pneumonia in mechanically ventilated trauma patients: endotracheal aspirate versus bronchoalveolar lavage. *J Trauma* 1993; 35: 512-7.
 27. Jourdain B, Novara A, Joly-Guillou ML, Dombret MC, Calvat S, Trouillet JL, Gibert C, Chastre J. Role of quantitative cultures of endotracheal aspirates in the diagnosis of nosocomial pneumonia. *Am J Respir Crit Care Med* 1995; 152: 241-6.
 28. Marquette CH, Copin MC, Wallet F, Neviere R, Saulnier F, Mathieu D, Durocher A, Ramon P, Tonnel AB. Diagnostic tests for pneumonia in ventilated patients: prospective evaluation of diagnostic accuracy using histology as a diagnostic gold standard. *Am J Respir Crit Care Med* 1995; 151: 1878-88.
 29. Wu CL, Yang Dle, Wang NY, Kuo HT, Chen PZ. Quantitative culture of endotracheal aspirates in the diagnosis of ventilator-associated pneumonia in patients with treatment failure. *Chest* 2002; 122: 662-8.
 30. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *Am J Respir Crit Care Med* 2000; 162: 505-11.

AUTHOR SUMMARY

Usefulness of Quantitative Endotracheal Aspirate Cultures in Intensive Care Unit Patients with Suspected Pneumonia

Yoon Mi Shin, Yeon-Mok Oh, Mi Na Kim, Tae Sun Shim, Chae-Man Lim, Sang Do Lee, Yoonsuck Koh, Woo Sung Kim, Dong Soon Kim and Sang-Bum Hong

This study shows that quantitative endotracheal aspirate culture is a useful non-invasive tool for the diagnosis of pneumonia pathogens in critically ill patients. A threshold level of 10^6 cfu/mL is appropriate because excellent concordance with quantitative BAL culture results was found.